Some factors suggest that the markets for corona virus vaccines will become much less profitable in upcoming years, following the World Health Organization’s (WHO) change to guidelines for vaccinations protecting against Covid-19, writes branch media FiercePharma with reference to data from GlobalData. 

WHO’s panel of experts disclosed the new guidelines a few weeks ago and no longer recommend a yearly booster shot as protection against the virus for healthy adults over age 60 who have already received the first two vaccines and an additional booster shot.

Simultaneously, the experts are no longer recommending that young people under the age of 18 be vaccinated. 

”Together with the latest guidance that encourages reduced use of boosters, as well as the US Senate’s decision to conclude the national emergency program ahead of schedule, the revenue streams from Covid-19 could dry out at a rapid pace,” GlobalData estimates in a statement.

According to FiercePharma, this could also mean that major vaccine manufacturers like Pfizer, Biontech and Moderne will have to further reduce their respective estimations for vaccine sales in 2023.

The latest prognosis from Pfizer warns of a dip in sales of its Covid vaccine, Comirnaty, to USD 13.5bn in 2023 from 37.8bn a year earlier.

Biontech expects a decrease to EUR 5bn (USD 5.5bn) from EUR 17.3bn (USD 18.9bn), and Moderna predicts 2023 sales at USD 5bn against 18.4bn the year prior.

In Denmark, Bavarian’s state-subsidized phase III study of a Covid vaccine has been delayed, and the results from the study are now expected to land in mid-2023.